-
Article
ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive disease characterized by remarkable intratumor heterogeneity (ITH), which poses therapeutic challenges. However, the clinical relevance and key determinant...
-
Article
Open AccessComprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities
Germline-somatic mutation interactions are universal and associated with tumorigenesis, but their role in breast cancer, especially in non-Caucasians, remains poorly characterized. We performed large-scale pro...
-
Article
Open AccessCalcifications in triple-negative breast cancer: Molecular features and treatment strategies
Despite the high prevalence of mammographic calcifications, our understanding remains limited regarding the clinical and molecular features of calcifications within triple-negative breast cancer (TNBC). To inv...
-
Article
Open AccessOmission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
Salvage mastectomy is traditionally recommended for patients who developed ipsilateral breast tumor recurrence (IBTR) in light of previous breast irradiation. However, it remains controversial whether surgical...
-
Article
Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor
Progression of triple-negative breast cancer (TNBC) constitutes a major unresolved clinical challenge, and effective targeted therapies are lacking. Because microtubule dynamics play pivotal roles in breast ca...
-
Article
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
Resistance to paclitaxel remains a major challenge in treating breast cancer. Our preclinical study suggested that TEKT4 germline variations in breast cancer are associated with paclitaxel resistance and increase...
-
Article
Open AccessCharacterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing
The remarkable advances in next-generation sequencing technology have enabled the wide usage of sequencing as a clinical tool. To promote the advance of precision oncology for breast cancer in China, here we r...
-
Article
Open AccessLncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
Estrogen receptor-positive (ER+) breast cancers represent approximately two-thirds of all breast cancers and have a sustained risk of late disease recurrence. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor...
-
Article
Open AccessAuthor Correction: Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.
-
Article
Open AccessCorrection to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer
After the publication of this work [1] an error in Fig. 1c was brought to our attention: the Western blots for PRDX6 and β-actin were similar to those shown in lanes 5-6 of Fig. 4g. To verify these findings, w...
-
Article
Open AccessMicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer
Emerging evidence suggests molecular and phenotypic association between treatment resistance and epithelial–mesenchymal transition (EMT) in cancer. Compared with the well-defined molecular events of miR-200a i...
-
Article
Open AccessImpact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer
We sought to investigate the impact of hormone receptor (HR) status and distant recurrence-free interval (DRFI) on the degree of overall survival (OS) benefit from palliative trastuzumab-containing treatment i...
-
Article
Open AccessA Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients
The value of sentinel lymph node biopsy (SLNB) in post-neoadjuvant chemotherapy (NCT) patients is still controversial. We aimed to identify predictors and construct a nomogram for predicting the pathologically...
-
Article
Open AccessA nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer
The response to neoadjuvant chemotherapy has been proven to predict long-term clinical benefits for patients. Our research is to construct a nomogram to predict pathological complete response of human epiderma...
-
Article
Open AccessComprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a highly heterogeneous group of cancers, and molecular subty** is necessary to better identify molecular-based therapies. While some classifiers have been established,...
-
Article
Open AccessLuminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China
The prognoses of young breast cancer patients are poor. The purpose of this study is to evaluate the different characteristics and prognoses among different subtypes of young breast cancer patients.
-
Article
Enriched variations in TEKT4 and breast cancer resistance to paclitaxel
Among chemotherapeutic agents, paclitaxel has shown great efficacy against breast cancer. Prediction of paclitaxel response may improve patient outcomes. Here we show, using exome sequencing, that in compariso...
-
Article
Open AccessClinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified
Few studies have addressed the biological features of medullary breast carcinoma (MBC) in the context of clinical outcomes. We sought to compare the baseline demographics, standard pathologic factors and long-...
-
Article
Open AccessTumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population
We sought to compare the baseline demographics, standard pathologic factors and long- term clinical outcomes between ILC and infiltrating ductal carcinoma (IDC) using a large database.
-
Article
RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer
Deleterious mutations in several genes that are involved in repair of damage to DNA have been associated with an increased risk of breast cancer. Recent studies have shown sequence variants in two such genes, ...
